Review Services
REVIEWS Comprehensive Global Review Services Ensure comprehensive ethics and safety oversight with Advarra’s full suite of ethical review committee services.
Reviews
Institutional Review Board (IRB) Services for Federal Grants
Simplify federal grant submissions with Advarra’s expert IRB support, offering compliance guidance and oversight for both single and multisite studies.
Institutional Review Board (IRB) Services for International Research
Advarra reviews research in the U.S., Puerto Rico, Canada, and limited minimal risk research outside these regions.
Institutional Biosafety Committee (IBC) Services Info Sheet
Advarra’s IBC services offer rapid, flexible solutions for IBC review, especially critical for gene therapy and other high-stakes research.
Institutional Review Board (IRB) Services Info Sheet
Advarra’s Institutional Review Board (IRB) offers expert guidance, supporting more than 3,500 institutions, academic medical centers, and site networks.
Endpoint Adjudication Committee (EAC) Services Info Sheet
Secure independent evaluation and adjudication of complex clinical trial endpoints.
Canadian Institutional Review Board / Research Ethics Board Services
Leverage Advarra’s expertise in Canada as the only officially recognized IRB/REB, offering extensive site reach and top-notch research ethics services.
Single Institutional Review Board (sIRB) Services Info Sheet
As the research community’s preferred sIRB partner, we help you meet regulatory requirements with efficiency and transparency.
Gene Therapy Ready Site Network
Advarra’s GTR Site Network includes 1,500+ vetted sites worldwide, fully prepared to support clinical trials in genetic engineering and advanced therapies.
Diversity, Equity, and Inclusion in Clinical Research
Achieving diversity, equity, and inclusion (DEI) in clinical trials is crucial for producing comprehensive and effective medical research benefitting all
Decentralized Clinical Trials Involving Biologics: Unique Challenges
Join this webinar to learn about FDA insights on DCTs and biologics. Dr. Eisenman discusses biosafety, risks, and key considerations for safe trials.
Preparing Your Action Plan for the FDA sIRB Mandate
Navigating research compliance often means addressing unseen challenges. Explore strategies to identify blind spots and strengthen oversight frameworks.